In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Higher fitness is associated with improved survival among cancer patients

Session Poster Session 1

Speaker Alexander Fardman

Event : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Prevention: Physical Inactivity
  • Session type : Poster Session

Authors : A Fardman (Tel Hashomer,IL), GD Banschick (Tel Aviv,IL), R Rabia (Tel Aviv,IL), S Segev (Tel Hashomer,IL), R Klempfner (Tel Hashomer,IL), D Fourey (Tel Hashomer,IL), R Percik (Tel Hashomer,IL), E Grossman (Tel Hashomer,IL), E Maor (Tel Hashomer,IL)

Authors:
A Fardman1 , GD Banschick2 , R Rabia2 , S Segev1 , R Klempfner1 , D Fourey1 , R Percik1 , E Grossman1 , E Maor1 , 1Chaim Sheba Medical Center - Tel Hashomer - Israel , 2Tel Aviv University - Tel Aviv - Israel ,

Citation:

Background: Cardio-respiratory fitness (CRF) is a known predictor of cardiovascular morbidity and mortality. However, data on the association of CRF with survival following a diagnosis of cancer is limited.

Purpose: To evaluate the association between CRF in a large cohort of asymptomatic adults and a probability of survival after subsequent cancer diagnosis.

Methods: We evaluated asymptomatic self-referred adults aged 40-79 years who were screened annually at a tertiary medical center. All subjects were free of cardiovascular disease and cancer at baseline and completed maximal exercise stress test according to the Bruce protocol. Fitness was categorized into age- and sex-specific quintiles (Q) according to Bruce protocol treadmill time with Q1-Q2 defined as low fitness and Q3-Q5 as higher fitness. Cancer data was available from a national cancer registry. The primary end point was all-cause mortality.

Results: Final study population in included 15,800 subjects. Mean age was 51±8 years and 72% were men. During median follow up of 13 years (IQR 7-16) 1,312 (8%) subjects developed cancer and 486 (3%) died. Most common cancer types were prostate in 302 (23%) and breast cancer in 189 (14%) patients. No difference was found in distribution of major cancer types between different fitness categories. Univariate Cox regression with cancer as a time dependent covariate showed that subjects who developed cancer during follow up were 19 times more likely to die (95% CI 15.5-22.5, p<.001). Kaplan Meier analysis showed that the cumulative probability of death from the time of cancer diagnosis was significantly lower among high fitness patients (34% ± 4% vs. 25% ± 3%, p Log rank =.008; Figure 1). Multivariate interaction analysis with cancer as a time dependent covariate showed that cancer-related risk of death was fitness-dependent, such that in the lower fitness group cancer was associated with 18 folds increased risk of death (95% CI 13.5-23) whereas among high fitness group the risk of death was lower (HR=13; 95% CI 10-17; p for interaction = .048).

Conclusions: Low CRF is associated with worse survival among subjects diagnosed as having cancer during follow up. These findings support the effectiveness of fitness assessment in preventive health care settings.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are